Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 10/20 | 0.42 |
| ▸ | CTSL | P07711 | 9/20 | 0.42 |
| ▸ | CTSB | P07858 | 6/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960946 | 0.90 | HTR2C (0.48) | HTR2CHTR2AHTR2BCTSSCTSL | |
| SCHEMBL3967475 | 0.89 | HTR2C (0.49) | HTR2CHTR2AHTR2BATM | |
| SCHEMBL3960316 | 0.87 | HTR2C (0.46) | HTR2CHTR2AHTR2BATM | |
| SCHEMBL3960312 | 0.87 | HTR2C (0.46) | HTR2CHTR2AHTR2BATM | |
| SCHEMBL3962497 | 0.86 | HTR2C (0.46) | HTR2CHTR2AHTR2BATM | |
| SCHEMBL3962501 | 0.86 | HTR2C (0.46) | HTR2CHTR2AHTR2BATM | |
| SCHEMBL3958249 | 0.86 | HTR2C (0.46) | HTR2CHTR2AHTR2BATM | |
| SCHEMBL3962619 | 0.85 | HTR2C (0.45) | HTR2CHTR2AHTR2BCTSSCTSL | |
| SCHEMBL3966050 | 0.84 | HTR2C (0.46) | HTR2CHTR2AHTR2BATM | |
| SCHEMBL3966045 | 0.84 | HTR2C (0.46) | HTR2CHTR2AHTR2BATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476687-B2 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2009-01-13 | — | — | US | disclosed |
| US-20090012291-A1 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20070135430-A1 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135430-A1 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | PTGIS, PTGIR, PTGS2 | HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885 |
| US-20090012291-A1 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | PTGIS, PTGIR, PTGS2 | HTR2C 646/4885HTR2A 1195/4885HTR2B 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.